Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-GPRC5D in R/R Multiple Myeloma and Plasma Cell Leukemia
NCT05759793Phase 1Recruiting
- Sponsor
- Reindeer Biotech
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD118 in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by Reindeer Biotech. Primary endpoints: Incidence of Dose-Limiting Toxicity at 28 days and Adverse Events at 2 years. Started Mar 2023; status: recruiting.
02
Drugs
RD118
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT05759793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759793.